CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
MIAMI, June 08, 2017 -- Progressive Care Inc. (OTC PINK:RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, health practice risk management, announces continued advancement during April and May 2017.
PharmCo filled nearly 36,000 prescriptions and realized revenues of over $3.3 million during the first two months of the second quarter, with nearly $1.9 million recognized in the month of May. This represents an 18% increase in revenue over the same period last year. PharmCo continues to drive revenue growth and increasing prescription counts through targeted interactions with physicians’ groups, clinics, and healthcare networks. The Company has been promoting its enhanced compliance and adherence techniques to healthcare providers under “full risk” contracts with insurance carriers. These programs and services have allowed the company to gain market penetration in Palm Beach County and the surrounding areas.
During the second quarter, the Company also began a full enterprise best practices evaluation. This process is designed to innovate new technologies, methods, services, procedures and protocols that will ensure PharmCo stays on the cutting edge of the pharmacy industry both now and in the future. The company routinely updates its model that best coincides with market and industry trends, but the ever increasing uncertainty in the healthcare space necessitates a more aggressive approach to improving standards. This also includes a concerted effort to recruit top talent to become members of the Board of Directors and senior management, as well as engaging reputable firms to represent the company and provide vital consultation.
“We are having a phenomenal year thus far,” stated S. Parikh Mars, CEO. “Though the challenges we face are many, we continue to push forward with an ambitious growth and development agenda. We have maintained a lean and fluid business that has allowed us to adapt to change and pressure while also being able to expand into open areas of opportunity. We know the remainder of the year will only get busier and that is a challenge we always welcome.”
About Progressive Care
Progressive Care, Inc. (OTC PINK:RXMD), through its subsidiary PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Contact Armen Karapetyan Senior Advisor Business Development [email protected]
